Drug updated on 11/10/2023
|Tablet (oral; 25 mg)
|Human immunodeficiency virus type 1 (HIV-1) specific, nonnucleoside reverse transcriptase inhibitor (NNRTI)
| Ongoing and
- Indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-naïve patients 12 years of age and older and weighing at least 35 kg with HIV-1 RNA less than or equal to 100,000 copies/mL.
- Indicated in combination with VOCABRIA (cabotegravir), for short-term treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.
Product Monograph / Prescribing Information
|Edurant (rilpivirine) Prescribing Information.
|Janssen Therapeutics, Titusville, NJ
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
|Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States.
|European AIDS Clinical Society
|Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV.
|Guidelines for the use of antiretroviral agents in adults and adolescents with HIV.
|NYSDOH AIDS Institute HIV Clinical Guideline.
|New York State Department of Health AIDS Institute
|Therapeutic guidelines for antiretroviral treatment of adult HIV infection.
|British Columbia Centre for Excellence in HIV/AIDS